Evidence map›Paper›PMID 23949768›Full record

ArticleThe Journal of investigative dermatology2013

Skin-specific drug delivery: a rapid solution to skin diseases?

Christian D Sadik, Detlef Zillikens

Abstract readComment
PubMed Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. There might be a role for CD200 in the pathogenesis of autoimmune and inflammatory skin disorders.Medical science monitor : international medical journal of experimental and clinical research · 2013
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Christian D SadikDepartment of Dermatology, Allergy, and Venereology, University of Lübeck, Lübeck, Germany. Christian.Sadik@uksh.de
Detlef Zillikens
Universitäres Kinderwunschzentrum Lübeck · DEUniversity of Lübeck · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this issue of The Journal of Investigative Dermatology, Kouno et al. achieve skin-specific drug delivery using an antibody to deliver substances in a highly specific manner to nontransformed cells. They make use of a nonpathogenic anti-desmoglein 3 autoantibody that had been derived from a patient with pemphigus vulgaris to deliver drugs to the surface of keratinocytes. This approach may turn out to be a new "magic bullet", thereby revolutionizing the therapy of skin disease. The authors then used a conjugate of this antibody with a new drug entity, TNF-related apoptosis-inducing ligand, to demonstrate, as a proof-of-principle, that their approach has the potential to facilitate the treatment of both cancerous and inflammatory skin diseases.

Indexed as

AnimalsAntibodies, MonoclonalDesmoglein 3Drug Delivery SystemsHumansKeratinocytesTNF-Related Apoptosis-Inducing LigandAntibodies, MonoclonalDesmoglein 3DSG3 protein, humanTNF-Related Apoptosis-Inducing LigandTNFSF10 protein, humanTnfsf10 protein, mouse

Identifiers

PMID23949768
OpenAlexW2047079903

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.